Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis

Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis Publisher Pubmed

Akbari H^{1, 2} ; Taghizadehhesary F³ ; Bahadori M⁴

Show Affiliations

1. Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Traditional Medicine School, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Professor Emeritus, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Mitochondrion Published:2022

Abstract

Immunotherapy based on programmed cell death protein-1 (PD-1) is a promising approach in oncology. However, a significant fraction of patients remain unresponsive. Therefore, it is imperative to clarify the relevant predictive factors. A decrease in cellular adenosine triphosphate (c-ATP) level can predispose to cellular dysfunction. ATP is a prerequisite for proper T cell migration and activation. Therefore, a decrease in the c-ATP level impairs T cell function and promotes cancer progression. This article gives an overview of the potential predictive factors of PD-1 blockade. Besides, it highlights the pivotal role of mitochondria in response to anti-PD-1 therapies. © 2021 Elsevier B.V. and Mitochondria Research Society

Related Docs

View other Related Docs

1. Targeted Anti-Mitochondrial Therapy: The Future of Oncology, Genes (2022)

2. Covid-19 Induced Liver Injury From a New Perspective: Mitochondria, Mitochondrion (2023)

3. Mitochondria As Playmakers of Car T-Cell Fate and Longevity, Cancer Immunology Research (2021)

4. The Powerful Immune System Against Powerful Covid-19: A Hypothesis, Medical Hypotheses (2020)

5. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)

6. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)

7. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)

8. Tumor Immunology, Clinical Immunology (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (9)

Hamid Reza Mirzaei (2)

Style	Citing Format
MLA	Akbari H, Taghizadehhesary F, Bahadori M. "Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis." Mitochondrion, vol. 62, no. , 2022, pp. 151-158.
APA	Akbari H, Taghizadehhesary F, Bahadori M (2022). Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion, 62(), 151-158.
Chicago	Akbari H, Taghizadehhesary F, Bahadori M. "Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis." Mitochondrion 62, no. (2022): 151-158.
Harvard	Akbari H, Taghizadehhesary F, Bahadori M (2022) 'Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis', Mitochondrion, 62(), pp. 151-158.
Vancouver	Akbari H, Taghizadehhesary F, Bahadori M. Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis. Mitochondrion. 2022;62():151-158.
BibTex	@article{ author = {Akbari H and Taghizadehhesary F and Bahadori M}, title = {Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis}, journal = {Mitochondrion}, volume = {62}, number = {}, pages = {151-158}, year = {2022} }
RIS	TY - JOUR AU - Akbari H AU - Taghizadehhesary F AU - Bahadori M TI - Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis JO - Mitochondrion VL - 62 IS - SP - 151 EP - 158 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract